Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 4/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.30 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262238 | 1.00 | ALDH1A1 (0.36) | ALDH1A1PTGS2LTA4HKIF11CYP3A4 | |
| SCHEMBL833709 | 1.00 | ALDH1A1 (0.36) | ALDH1A1PTGS2LTA4HKIF11CYP3A4 | |
| Selenium SCHEMBL30525936 | 0.98 | ALDH1A1 (0.35) | ALDH1A1PTGS2LTA4HKIF11 | |
| Hydrochloric Acid SCHEMBL852606 | 0.98 | ALDH1A1 (0.38) | ALDH1A1PTGS2LTA4HKIF11 | |
| Hydrochloric Acid SCHEMBL9081237 | 0.98 | ALDH1A1 (0.38) | ALDH1A1PTGS2LTA4HKIF11 | |
| Hydrochloric Acid SCHEMBL940526 | 0.98 | ALDH1A1 (0.38) | ALDH1A1PTGS2LTA4HKIF11 | |
| Hydrochloric Acid SCHEMBL4389612 | 0.98 | ALDH1A1 (0.38) | ALDH1A1PTGS2LTA4HKIF11 | |
| Hydrochloric Acid SCHEMBL1375315 | 0.98 | ALDH1A1 (0.38) | ALDH1A1PTGS2LTA4HKIF11 | |
| Hydrochloric Acid SCHEMBL703118 | 0.98 | ALDH1A1 (0.38) | ALDH1A1PTGS2LTA4HKIF11 | |
| SCHEMBL2824144 | 0.96 | ALDH1A1 (0.34) | ALDH1A1PTGS2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017180535-A1 | CHIRAL PEPTIDES | CARNOT, LLC (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2011107948-A2 | LIGANDS OF INSULIN DEGRADING ENZYME AND THEIR USES | UNIVERSITE LILLE 2 DROIT ET SANTE (FR) | 2011-09-09 | — | — | WO | disclosed |
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1572065-A2 | METHOD AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS | Rappaport Family Institute for Research in the Medical Sciences (IL) | 2005-09-14 | — | — | EP | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
| EP-1311488-A1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | Pfizer Limited (GB) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002098346-A2 | METHOD AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2002-12-12 | — | — | WO | disclosed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002014285-A1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LIMITED (GB) | 2002-02-21 | — | — | WO | disclosed |
| US-4937352-A | REACTING HISTIDINE DERIVATIVE WITH PHOSGENE, ALKYLATING, HYDROLYZING | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-06-26 | — | — | US | disclosed |
| US-4772721-A | INTERMEDIATES FOR PROTEINS, ENZYMES | DIAMALT AG (DE) | 1988-09-20 | — | — | US | disclosed |
| EP-0129254-A2 | Process for the preparation of N-tau-substituted histidine derivatives, the N-tau-substituted histidine derivatives and their use | DIAMALT AKTIENGESELLSCHAFT (DE) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147229-A1 | Pharmaceuticals | BDKRB1, TFPI, BDKRB2 | ALDH1A1 1013/4885PTGS2 781/4885LTA4H 109/4885 |
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | ALDH1A1 1449/4885PTGS2 655/4885LTA4H 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.